WO2022163466A1 - オリゴデンドロサイトの作製方法 - Google Patents
オリゴデンドロサイトの作製方法 Download PDFInfo
- Publication number
- WO2022163466A1 WO2022163466A1 PCT/JP2022/001814 JP2022001814W WO2022163466A1 WO 2022163466 A1 WO2022163466 A1 WO 2022163466A1 JP 2022001814 W JP2022001814 W JP 2022001814W WO 2022163466 A1 WO2022163466 A1 WO 2022163466A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- oligodendrocytes
- producing
- inducer
- progenitor cells
- Prior art date
Links
- 210000004248 oligodendroglia Anatomy 0.000 title claims abstract description 111
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 75
- 210000004027 cell Anatomy 0.000 claims abstract description 394
- 210000000130 stem cell Anatomy 0.000 claims abstract description 94
- 239000000411 inducer Substances 0.000 claims abstract description 92
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 26
- 230000008672 reprogramming Effects 0.000 claims description 92
- 238000010899 nucleation Methods 0.000 claims description 25
- 210000005087 mononuclear cell Anatomy 0.000 claims description 15
- 230000004663 cell proliferation Effects 0.000 claims description 14
- 238000010367 cloning Methods 0.000 claims description 13
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 9
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 15
- 241000711408 Murine respirovirus Species 0.000 description 91
- 239000013598 vector Substances 0.000 description 81
- 239000002609 medium Substances 0.000 description 70
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 65
- 230000035772 mutation Effects 0.000 description 47
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 230000003612 virological effect Effects 0.000 description 22
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 18
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 18
- 101100462520 Mus musculus Tp53 gene Proteins 0.000 description 16
- 241000282412 Homo Species 0.000 description 14
- 210000001778 pluripotent stem cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- -1 for example Proteins 0.000 description 10
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 9
- 102100034574 P protein Human genes 0.000 description 9
- 101710181008 P protein Proteins 0.000 description 9
- 101710177166 Phosphoprotein Proteins 0.000 description 9
- 102100022142 Achaete-scute homolog 1 Human genes 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 101000901099 Homo sapiens Achaete-scute homolog 1 Proteins 0.000 description 8
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 8
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000002073 fluorescence micrograph Methods 0.000 description 7
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 6
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 6
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 6
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 description 6
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 6
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000002469 basement membrane Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 102220599936 Disks large-associated protein 5_G69E_mutation Human genes 0.000 description 4
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 4
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 4
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 108700025694 p53 Genes Proteins 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 3
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000005732 intercellular adhesion Effects 0.000 description 3
- 108010038862 laminin 10 Proteins 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 101150034814 F gene Proteins 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 description 2
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 2
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 2
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
- 101150062031 L gene Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000055324 Myelin Proteolipid Human genes 0.000 description 2
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000005258 dental pulp stem cell Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920002883 poly(2-hydroxypropyl methacrylate) Polymers 0.000 description 2
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 2
- 229920002189 poly(glycerol 1-O-monomethacrylate) polymer Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100037124 Developmental pluripotency-associated 5 protein Human genes 0.000 description 1
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 description 1
- 102100037126 Developmental pluripotency-associated protein 4 Human genes 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100037060 Forkhead box protein D3 Human genes 0.000 description 1
- 102100041002 Forkhead box protein H1 Human genes 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101150008820 HN gene Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000881848 Homo sapiens Developmental pluripotency-associated 5 protein Proteins 0.000 description 1
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101000881868 Homo sapiens Developmental pluripotency-associated protein 4 Proteins 0.000 description 1
- 101001029308 Homo sapiens Forkhead box protein D3 Proteins 0.000 description 1
- 101000892840 Homo sapiens Forkhead box protein H1 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 1
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 1
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 description 1
- 101000603323 Homo sapiens Nuclear receptor subfamily 0 group B member 1 Proteins 0.000 description 1
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 101000958664 Homo sapiens Nucleus accumbens-associated protein 1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000984033 Homo sapiens Protein lin-28 homolog B Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000740204 Homo sapiens Sal-like protein 2 Proteins 0.000 description 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 1
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 1
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 101000784538 Homo sapiens Zinc finger and SCAN domain-containing protein 10 Proteins 0.000 description 1
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 1
- 101000857270 Homo sapiens Zinc finger protein GLIS1 Proteins 0.000 description 1
- 101000976645 Homo sapiens Zinc finger protein ZIC 3 Proteins 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 1
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102100035077 Myoblast determination protein 1 Human genes 0.000 description 1
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 1
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 1
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 102100025459 Protein lin-28 homolog B Human genes 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 101150020201 RB gene Proteins 0.000 description 1
- 101001031368 Rattus norvegicus Histone H2A type 4 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100037205 Sal-like protein 2 Human genes 0.000 description 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 1
- 108010048349 Steroidogenic Factor 1 Proteins 0.000 description 1
- 102100029856 Steroidogenic factor 1 Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 102100020919 Zinc finger and SCAN domain-containing protein 10 Human genes 0.000 description 1
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 1
- 102100025883 Zinc finger protein GLIS1 Human genes 0.000 description 1
- 102100023495 Zinc finger protein ZIC 3 Human genes 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 108091072810 miR-294 stem-loop Proteins 0.000 description 1
- 108091076076 miR-295 stem-loop Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 229920001507 poly(N-isopropylacrylamide-co-acrylamide) Polymers 0.000 description 1
- 229920001504 poly(N-isopropylacrylamide-co-acrylic acid) Polymers 0.000 description 1
- 229920001487 poly(N-isopropylacrylamide-co-butylacrylate) Polymers 0.000 description 1
- 229920001501 poly(N-isopropylacrylamide-co-methacrylic acid) Polymers 0.000 description 1
- 229920001511 poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/086—Coculture with; Conditioned medium produced by cells of the nervous system glial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Definitions
- the present invention relates to cell technology, and to methods for producing oligodendrocytes and their progenitor cells.
- Oligodendrocytes which are myelin-forming cells in the central nervous system, may be useful for cell transplantation of hereditary and acquired leukodystrophies (see, for example, Patent Documents 1 and 2).
- conventional methods for inducing oligodendrocytes from stem cells are problematic in that they are time consuming and inefficient.
- One of the objects of the present invention is to provide an efficient method for producing oligodendrocytes and their progenitor cells.
- a method for producing oligodendrocytes and their progenitor cells comprises introducing inducers including OLIG and SOX into iPS cells or ES cells.
- methods for producing oligodendrocytes and their progenitor cells comprise introducing inducers including OLIG and NKX into iPS cells or ES cells.
- a method for producing oligodendrocytes and their progenitor cells which comprises introducing inducers including OLIG, NKX, and SOX into iPS cells or ES cells.
- the inducer may further contain a factor that promotes cell proliferation.
- the factor that promotes cell proliferation is at least one selected from the group consisting of p53 gene-repressing factors, Rb gene-repressing factors, and MYC.
- MYC may be c-MYC.
- the inducer may further contain ASCL.
- a method for producing oligodendrocytes and their progenitor cells which comprises introducing inducers including OLIG and factors that promote cell proliferation into iPS cells or ES cells.
- the factor that promotes cell proliferation is at least one selected from the group consisting of p53 gene-repressing factors, Rb gene-repressing factors, and MYC.
- MYC may be c-MYC.
- the inducer may contain at least one selected from the group consisting of SOX, ASCL, and NKX.
- an oligodendro oligodendro which includes producing iPS cells without cloning cells into which a reprogramming factor has been introduced, and introducing an inducer including OLIG into the iPS cells.
- the steps include seeding cells into which a reprogramming factor has been introduced to produce iPS cells without cloning, and introducing an inducer including OLIG into the iPS cells.
- an inducer including OLIG into the iPS cells.
- the cells into which the reprogramming factor has been introduced are detached from the culture vessel, and at least a portion of the detached cells are mixed and seeded to produce iPS cells; Introducing an inducer comprising OLIG is provided.
- the cells into which the reprogramming factor has been introduced are recovered from the culture vessel, and at least a portion of the recovered cells are mixed and seeded to produce iPS cells; Introducing an inducer comprising OLIG is provided.
- iPS cells are produced without picking up each of a plurality of colonies formed by cells into which a reprogramming factor has been introduced, and an inducer containing OLIG is introduced into the iPS cells.
- a method for producing oligodendrocytes and their progenitor cells comprising:
- iPS cells are prepared by seeding a mixture of cells into which a reprogramming factor has been introduced, which are derived from different single cells, and iPS cells containing OLIG. Introducing a factor is provided.
- the cells do not have to be cloned in seeding.
- cells into which reprogramming factors have been introduced may be mixed during seeding.
- clones of cells into which reprogramming factors have been introduced may be mixed during seeding.
- oligodendrocytes and their progenitor cells In the method for producing oligodendrocytes and their progenitor cells described above, different clones of reprogramming factor-introduced cells may be mixed in seeding.
- the above-described method for producing oligodendrocytes and their progenitor cells may not include cloning a single colony formed by cells into which a reprogramming factor has been introduced.
- the above method for producing oligodendrocytes and their progenitor cells may not include picking up colonies formed by cells into which reprogramming factors have been introduced.
- the cells into which the reprogramming factor has been introduced and which are attached to the culture vessel are collected, and at least part of the collected cells are seeded in a medium.
- the cells into which the reprogramming factor has been introduced may be seeded without discrimination by gene expression state.
- the cells into which the reprogramming factor has been introduced may be seeded without distinguishing the degree of reprogramming.
- the inducer may contain at least one selected from the group consisting of SOX, ASCL, and NKX.
- a method for producing oligodendrocytes and their progenitor cells which comprises introducing inducers including OLIG, SOX, ASCL, and NKX into somatic cells.
- the inducer may further contain a factor that promotes cell proliferation.
- a method for producing oligodendrocytes and their progenitor cells which comprises introducing inducers including OLIG and factors that promote cell proliferation into somatic cells.
- the inducer may contain at least one selected from the group consisting of SOX, ASCL, and NKX.
- the factor that promotes cell proliferation is at least one selected from the group consisting of p53 gene-repressing factors, Rb gene-repressing factors, and MYC.
- MYC may be c-MYC.
- the somatic cells need not be iPS cells or ES cells.
- the somatic cells may be blood cells.
- the somatic cells may be mononuclear cells.
- the somatic cells may be fibroblasts.
- FIG. 4 is a graph showing measurement results by a flow cytometer according to Example 1.
- FIG. 4 is a graph showing the results of PCR according to Example 1.
- FIG. 1 is a photograph showing TRA1-60 positive cells according to Example 1.
- FIG. 4 is a graph showing clonal efficiencies according to Examples 1 and 2.
- FIG. 4 is a fluorescence micrograph of cells according to Example 3.
- FIG. 4 is a fluorescence micrograph of cells according to Example 3.
- FIG. 4 is a fluorescence micrograph of cells according to Example 4.
- FIG. 10 is a fluorescence micrograph of cells according to Examples 5 to 9.
- FIG. 10 is a fluorescence micrograph of cells according to Example 10.
- FIG. 11 is a fluorescence micrograph of cells according to Example 11.
- FIG. 12 is a fluorescence micrograph of cells according to Example 12.
- FIG. 2 is a graph showing the results of Examples 13-18.
- a method for producing oligodendrocytes and their progenitor cells includes introducing inducers including OLIG, SOX, ASCL, and NKX into somatic cells.
- the method for producing oligodendrocytes and their progenitor cells includes introducing inducers including OLIG and SOX into iPS cells (induced pluripotent stem cells) or ES cells (embryonic stem cells).
- inducers including OLIG and SOX into iPS cells (induced pluripotent stem cells) or ES cells (embryonic stem cells).
- the method for producing oligodendrocytes and their progenitor cells includes introducing inducers including OLIG and NKX into iPS cells or ES cells.
- the method for producing oligodendrocytes and their progenitor cells is to produce iPS cells without cloning cells into which a reprogramming factor has been introduced, and to introduce an inducer containing OLIG into the iPS cells.
- the method for producing oligodendrocytes and their progenitor cells includes producing iPS cells by seeding cells into which a reprogramming factor has been introduced without cloning, and iPS cells containing an inducer containing OLIG. and introducing
- the cells into which the reprogramming factor has been introduced are detached from the culture vessel, and at least part of the detached cells are mixed and seeded to produce iPS cells. and introducing an inducer comprising an OLIG into iPS cells.
- cells into which a reprogramming factor has been introduced are recovered from a culture vessel, and at least a portion of the recovered cells are mixed and seeded to produce iPS cells. and introducing an inducer comprising an OLIG into iPS cells.
- the method for producing oligodendrocytes and their progenitor cells comprises producing iPS cells without picking up each of a plurality of colonies formed by cells into which a reprogramming factor has been introduced; introducing an inducer comprising
- iPS cells are produced by seeding a mixture of cells into which a reprogramming factor has been introduced, which are derived from different single cells. and introducing an inducer comprising an OLIG into the iPS cells.
- Inducers may include OLIG and ASCL. Inducers may include OLIG, ASCL, and SOX. Inducers may include OLIG, SOX, ASCL, and NKX.
- OLIG is, for example, OLIG2.
- SOX is, for example, SOX10.
- ASCL is, for example, ASCL1.
- NKX is, for example, NKX2.2 or NKX6.1.
- the inducer may further contain a factor that promotes cell proliferation.
- factors that promote cell proliferation include factors that repress the p53 gene, factors that repress the Rb gene, and MYC.
- a factor that promotes cell proliferation can be a factor that promotes canceration, a factor that suppresses apoptosis, or a factor that induces chromatin to euchromatin.
- p53 is a cancer suppressor protein.
- Factors that repress the p53 gene are, for example, dominant-negative mutants of p53.
- the dominant-negative mutant of p53 is not particularly limited as long as it can act competitively with the wild-type p53 protein endogenously present in somatic cells to inhibit the function of the wild-type p53 protein.
- Examples of dominant-negative mutants of p53 include p53P275S, in which proline at position 275 (position 278 in humans) located in the DNA-binding region of mouse p53 is mutated to serine; p53DD in which amino acids at positions 11 to 304 in p53) are deleted, p53S58A in which serine at position 58 (position 61 in human) of mouse p53 is mutated to alanine, position 135 in human p53 (position 135 in mouse) p53C135Y with a point mutation of cysteine at position 132 in the case of mouse p53 to tyrosine, p53A135V with a point mutation of alanine at position 135 in mouse p53 (position 138 in the case of humans) to valine, and position 172 of mouse p53 (position 132 in the case of humans).
- the agent that suppresses the p53 gene can be an RNA such as short hairpin RNA (shRNA) and siRNA that interferes with the p53 gene.
- Rb is a cancer suppressor protein.
- Agents that suppress the Rb gene can be RNAs such as, for example, short hairpin RNAs (shRNAs) and siRNAs that interfere with the Rb gene.
- shRNAs short hairpin RNAs
- siRNAs that interfere with the Rb gene.
- MYC loses the function of cell cycle control and induces canceration.
- MYC may be c-MYC.
- the inducer may be DNA or RNA.
- RNA may be mRNA.
- human gene symbols are used here, capital letters and small letters are not intended to limit species. For example, all capital letters do not exclude the inclusion of mouse or rat genes. However, in the examples, gene symbols are indicated according to the species actually used.
- Somatic cells are, for example, cells that are not stem cells. Somatic cells are, for example, cells other than iPS cells and ES cells. Examples of somatic cells include fibroblasts, blood cells, dental pulp stem cells, keratinocytes, dermal papilla cells, oral epithelial cells, and somatic stem progenitor cells. Examples of blood cells include T cells and blood cells other than T cells (non-T cells) such as macrophages, monocytes, monocytes, B cells, and non-rosette forming cells. The somatic cells may be cells contained in urine. Examples of cells contained in urine include bladder epithelial cells.
- Somatic cells may be human-derived or non-human animal-derived.
- a somatic cell may be derived from one human, or may be derived from multiple humans.
- a somatic cell may be derived from one non-human animal or may be derived from multiple non-human animals.
- Somatic cells may be of fetal origin.
- iPS cells and ES cells may be human-derived or non-human animal-derived.
- the iPS cells and ES cells may be derived from one human, or may be derived from multiple humans.
- iPS cells and ES cells may be derived from one non-human animal, or may be derived from multiple non-human animals.
- iPS cells may be of fetal origin.
- culturing cells introduced with a reprogramming factor, collecting the cells introduced with the reprogramming factor, seeding at least a part of the collected cells in a medium and subculturing may be induced by a culture method, including
- Cells into which reprogramming factors are introduced are not particularly limited, but examples include fibroblasts, blood cells, dental pulp stem cells, keratinocytes, dermal papilla cells, oral epithelial cells, and somatic stem progenitor cells.
- Cells into which reprogramming factors are introduced may be cells contained in urine. Examples of cells contained in urine include bladder epithelial cells.
- Cells into which reprogramming factors are introduced may be derived from humans or non-human animals.
- a cell into which a reprogramming factor is introduced may be derived from one human, or may be derived from multiple humans.
- the cells into which the reprogramming factor is introduced may be derived from one non-human animal or multiple non-human animals.
- a reprogramming factor introduced into a cell is, for example, RNA.
- RNA is, for example, mRNA.
- Reprogramming factors introduced into cells include, for example, OCT RNA such as OCT3/4, SOX RNA such as SOX2, KLF RNA such as KLF4, and MYC RNA such as c-MYC.
- OCT3/4-modified M 3 O may be used as a reprogramming factor RNA.
- reprogramming factor RNA is LIN28A, FOXH1, LIN28B, GLIS1, p53-dominant negative, p53-P275S, L-MYC, NANOG, DPPA2, DPPA4, DPPA5, ZIC3, BCL-2, E-RAS, TPT1, SALL2 , NAC1, DAX1, TERT, ZNF206, FOXD3, REX1, UTF1, KLF2, KLF5, ESRRB, miR-291-3p, miR-294, miR-295, NR5A1, NR5A2, TBX3, MBD3sh, TH2A, TH2B, and P53DD It may further contain RNA of at least one factor selected from the group consisting of. These RNAs are available from TriLink.
- p53 is a cancer suppressor protein.
- the dominant-negative mutant of p53 is not particularly limited as long as it can act competitively with the wild-type p53 protein endogenously present in somatic cells to inhibit the function of the wild-type p53 protein.
- Examples of dominant-negative mutants of p53 include p53P275S, in which proline at position 275 (position 278 in humans) located in the DNA-binding region of mouse p53 is mutated to serine; p53DD in which amino acids at positions 11 to 304 in p53) are deleted, p53S58A in which serine at position 58 (position 61 in human) of mouse p53 is mutated to alanine, position 135 in human p53 (position 135 in mouse) p53C135Y with a point mutation of cysteine at position 132 in the case of mouse p53 to tyrosine, p53A135V with a point mutation of alanine at position 135 in mouse
- p53R172H with a point mutation of arginine to histidine at position 175) of mouse p53
- p53R270H with a point mutation of arginine to histidine at position 270 (position 273 in humans) of mouse p53
- position 278 position 281 in humans of mouse p53.
- p53D278N in which the aspartic acid at position ) is mutated to asparagine.
- RNA may be modified with pseudouridine ( ⁇ ) or 5-methyluridine (5meU). RNA may be polyadenylated.
- the RNA introduced into the cell is, for example, single-stranded RNA, and double-stranded RNA may be substantially removed. Moreover, it is preferable that impurities such as short-chain RNA and contaminants are substantially removed from the RNA to be introduced into the cells.
- Single-stranded RNA introduced into cells may be purified and/or concentrated to substantially remove double-stranded RNA. Methods for purifying single-stranded RNA to be introduced into cells include a purification method using high performance liquid chromatography (HPLC). For example, HPLC removes 70% or more, 75% or more, 80% or more, 85% or more, or 90% or more of double-stranded RNA.
- HPLC high performance liquid chromatography
- the RNA introduced into the cells may be treated with a ribonuclease that degrades double-stranded RNA to substantially remove double-stranded RNA.
- the RNA to be introduced into the cell may further comprise MYOD transcriptional activation domain (TAD) RNA directly connected to the full-length OCT3/4 RNA.
- TAD MYOD transcriptional activation domain
- the lipofection method is a method in which a complex of a nucleic acid, which is a negatively charged substance, and a positively charged lipid is formed through electrical interaction, and the complex is taken up into cells by endocytosis or membrane fusion. .
- the lipofection method has advantages such as little damage to cells, excellent transfection efficiency, simple operation, and short time.
- a reprogramming factor is introduced into cultured cells using, for example, an RNA transfection reagent.
- an RNA transfection reagent for example, if the cells are mononuclear cells, the RNA may be introduced into the mononuclear cells immediately after their isolation from the blood.
- a viral vector may be an RNA viral vector.
- the RNA virus vector may be a Sendai virus vector.
- the Sendai virus vector may be a temperature-sensitive Sendai virus vector in which the stability of the viral nucleic acid is reduced above a predetermined temperature.
- the viral nucleic acid of the temperature-sensitive Sendai virus vector is stable below a certain temperature.
- the viral nucleic acid may be viral DNA or viral RNA.
- a viral nucleic acid may be a viral genome. The reduction in viral nucleic acid stability may be at least one of degradation of the viral nucleic acid and inhibition of replication or proliferation of the viral nucleic acid.
- the predetermined temperature is, for example, 36.5° C. or higher and 37.5° C. or lower.
- the stability of the viral nucleic acid of the temperature-sensitive Sendai virus vector ie at least one of the growth, replication rate and gene expression level, is high below a predetermined temperature and low above a predetermined temperature.
- the temperature-sensitive Sendai virus vector has a growth rate or gene expression level in cells cultured at 37°C that is half or less than the growth rate or gene expression level in cells cultured at 32°C. is.
- the Sendai virus encodes the N gene, P gene, M gene, F/HN gene, and L gene.
- the HN protein recognizes sialic acid on the cell surface and tethers the virus particles to the cell when the Sendai virus attaches to the cell.
- the F protein is cleaved and activated by an extracellular protease to catalyze the fusion of the tethered Sendai virus envelope and the plasma membrane of the target cell, thereby establishing infection.
- the L protein, together with its modification protein, the P protein catalyzes replication of viral nucleic acids and transcription from the replicated multi-copy nucleic acids in the cytoplasm after infection.
- the Sendai virus vector By deleting the F gene in the Sendai virus vector, it is possible to suppress the production of infectious virus particles from transfected cells.
- the Sendai virus vector can be made temperature-sensitive by introducing a mutation into at least one of the L gene and the P gene.
- TS7 Y942H/L1361C/L1558I mutation of L protein
- TS12 D433A/R434A/K437A mutation of P protein
- TS13 D433A/R434A/K437A of P protein mutation and L1558I mutation of L protein
- TS14 D433A/R434A/K437A mutation of P protein and L1361C mutation of L protein
- TS15 D433A/R434A/K437A mutation of P protein and L1361C/L1558I mutation of L protein
- the Sendai virus vector has, for example, G69E, T116A, and A183S mutations in the M protein, A262T, G264R, and K461G mutations in the HN protein, L511F mutation in the P protein, and N1197S in the L protein. and an F gene-deleted ( ⁇ F) Sendai virus vector having the K1795E mutation, which is a Sendai virus vector into which the above-mentioned TS7, TS12, TS13, TS14, or TS15 mutation has been introduced.
- temperature-sensitive mutations of Sendai virus vectors are not limited to these.
- the Sendai virus vector is, for example, SeV(PM)/TS ⁇ F, SeV18+/TS ⁇ F, or SeV(HNL)/TS ⁇ F, and is a Sendai virus vector introduced with the above TS7, TS12, TS13, TS14, or TS15 mutation. be.
- temperature-sensitive mutations of Sendai virus vectors are not limited to these.
- the Sendai virus vector to be introduced into cells may be a combination of a temperature-sensitive Sendai virus vector and a temperature-insensitive Sendai virus vector.
- the Sendai virus vector to be introduced into the cell may be only the temperature-sensitive Sendai virus vector and may not contain the temperature-insensitive Sendai virus vector.
- the Sendai virus vector to be introduced into cells may be only a temperature-sensitive Sendai virus vector introduced with the TS7, TS12, TS13, TS14, or TS15 mutation, and may not contain a temperature-insensitive Sendai virus vector.
- the Sendai virus vector to be introduced into cells is only a Sendai virus vector that has the same or higher temperature sensitivity than the temperature-sensitive Sendai virus vector into which the TS7, TS12, TS13, TS14, or TS15 mutation is introduced. It does not have to contain a viral vector.
- the Sendai virus vector to be introduced into cells is only a Sendai virus vector having temperature sensitivity equal to or higher than that of the temperature-sensitive Sendai virus vector introduced with the TS7, TS12, TS13, TS14, or TS15 mutation.
- the Sendai virus vector which is less temperature sensitive than the temperature-sensitive Sendai virus vector into which the TS13, TS14, or TS15 mutation is introduced, may not be included.
- the Sendai virus vector introduced into cells carries any reprogramming factor.
- the Sendai virus vector to be introduced into the cell contains, for example, KLF RNA, OCT RNA, and SOX RNA in this order, a temperature-sensitive Sendai virus vector that does not contain MYC RNA, and a temperature-sensitive Sendai virus vector that contains MYC RNA and KLF.
- RNA, OCT RNA, and a temperature-sensitive Sendai virus vector that does not contain SOX RNA are arbitrary and are not particularly limited.
- the Sendai virus vector to be introduced into the cell may contain a Sendai virus vector that contains KLF RNA and does not contain OCT RNA and SOX RNA.
- the Sendai virus vector containing KLF RNA and not containing OCT RNA and SOX RNA may be a temperature-sensitive Sendai virus vector or a temperature-insensitive Sendai virus vector.
- a temperature-sensitive Sendai virus vector containing KLF RNA, OCT RNA, and SOX RNA has, for example, G69E, T116A, and A183S mutations in the M protein and A262T, G264R, and K461G mutations in the HN protein.
- Temperature-sensitive mutations are, for example, TS7 or TS12, or TS12.
- a temperature-sensitive Sendai virus vector comprising KLF RNA, OCT RNA, and SOX RNA is, for example, SeV(PM)KOS/TS7 ⁇ F or SeV(PM)KOS/TS12 ⁇ F, or SeV(PM)KOS/TS12 ⁇ F. be.
- a temperature-sensitive Sendai virus vector containing MYC RNA has, for example, G69E, T116A, and A183S mutations in the M protein, A262T, G264R, and K461G mutations in the HN protein, and L511F mutation in the P protein. and the F gene-deleted Sendai virus vector having the N1197S and K1795E mutations in the L protein, which is a Sendai virus vector having the above mutations of TS7, TS12, TS13, TS14, or TS15.
- a temperature sensitive mutation is for example TS15.
- a temperature-sensitive Sendai virus vector containing MYC RNA is, for example, SeV(HNL)MYC/TS12 ⁇ F, SeV(HNL)MYC/TS13 ⁇ F, or SeV(HNL)MYC/TS15 ⁇ F, or SeV(HNL)MYC/TS15 ⁇ F. be.
- a Sendai virus vector containing KLF RNA and not containing OCT RNA and SOX RNA has, for example, G69E, T116A, and A183S mutations in the M protein and A262T, G264R, and K461G mutations in the HN protein. It is an F gene-deleted Sendai virus vector having an L511F mutation in the P protein and N1197S and K1795E mutations in the L protein.
- a Sendai virus vector containing KLF RNA and not containing OCT RNA and SOX RNA is, for example, weaker in temperature sensitivity than the Sendai virus vector introduced with the above-mentioned TS7, TS12, TS13, TS14, or TS15 mutation,
- the KLF gene can be expressed even at temperatures above .
- a Sendai virus vector containing KLF RNA and not containing OCT RNA and SOX RNA is, for example, SeV18+KLF4/TS ⁇ F.
- Sendai virus vectors When introducing multiple types of Sendai virus vectors into cells, for example, multiple types of Sendai virus vectors are simultaneously introduced into cells. Alternatively, it is preferable to introduce all types of Sendai virus vectors into cells within 48 hours after the introduction of one type of Sendai virus vector into cells.
- the multiplicity of infection (MOI) of the Sendai virus vector when infecting cells is, for example, 0.1 or more. Moreover, MOI is 100 or less, for example.
- the temperature at which the cells are infected with the Sendai virus vector should be below a predetermined temperature at which the stability of the viral nucleic acid of the temperature-sensitive Sendai virus vector decreases, that is, the temperature at which the viral nucleic acid of the temperature-sensitive Sendai virus vector is stable. or above a predetermined temperature.
- the temperature at which cells are infected with the Sendai virus vector reduces the stability of the viral nucleic acid of the temperature-sensitive Sendai virus vector.
- the temperature is preferably lower than the predetermined temperature, that is, the temperature at which the viral nucleic acid of the temperature-sensitive Sendai virus vector is stable.
- Cells into which reprogramming factors are introduced may be adherent or suspension cultured.
- Somatic cells introduced with reprogramming factors are feeder-free using basement membrane matrices such as Matrigel (Corning), CELLstart®, Laminin 511 (iMatrix-511, nippi), fibronectin, and vitrotin. It may be cultured.
- basement membrane matrices such as Matrigel (Corning), CELLstart®, Laminin 511 (iMatrix-511, nippi), fibronectin, and vitrotin. It may be cultured.
- Examples of media in which cells into which reprogramming factors are introduced are cultured include human ES/iPS media such as Primate ES Cell Medium (ReproCELL), Stemfit AK02N, Stemfit AK03 (Ajinomoto), and TeSR-E8 (STEMCELL Technologies).
- Stem cell culture medium such as can be used.
- Stem cell culture medium is placed in an incubator such as, for example, a dish, well, or tube.
- At least 2 days, or 2 to 10 days after infecting the cells with the Sendai virus vector, at a temperature lower than a predetermined temperature at which the stability of the viral nucleic acid of the temperature-sensitive Sendai virus vector decreases, that is, the temperature-sensitive Sendai virus Cells may be cultured at a temperature at which the viral nucleic acid of the vector is stable. After that, the cells may be cultured at a predetermined temperature or higher. While culturing the cells at a predetermined temperature or higher, the medium may be changed, for example, once every two days.
- the cells After infecting the cells with the Sendai virus vector, the cells may be cultured at a temperature of at least 2 days, or 2 to 10 days, for example, at a temperature of 4.0°C or higher and lower than 37.0°C. Thereafter, the temperature is raised, and the cells may be cultured at a temperature of 36.5°C or higher and 40.0°C or lower. The temperature may be raised once or may be raised stepwise. After raising the temperature, the medium may be changed while culturing the cells, eg every two days.
- the viral nucleic acid of the temperature-sensitive Sendai virus vector is below a predetermined temperature at which the stability of the viral nucleic acid of the temperature-sensitive Sendai virus vector decreases until stem cell-like colonies begin to appear.
- Cells may be cultured at a temperature that is stable. After stem cell-like colonies begin to appear, the cells may be cultured at a predetermined temperature or higher. While culturing the cells at a predetermined temperature or higher, the medium may be changed, for example, once every two days.
- the cells may be cultured at a temperature of, for example, 4.0°C or higher and lower than 37.0°C until stem cell-like colonies begin to appear. After stem cell-like colonies begin to appear, the temperature is increased and the cells may be cultured at temperatures above 36.5°C and below 40.0°C. The temperature may be raised once or may be raised stepwise. After raising the temperature, the medium may be changed while culturing the cells, eg every two days.
- the cells introduced with the reprogramming factor are recovered, and at least a part of the recovered and mixed cells is seeded in a medium for at least one passage.
- the reprogramming factor-introduced cells may be collected, and at least a portion of the collected mixed cells may be seeded in culture medium and passaged until stem cells are established. In addition, all of the collected mixed cells may be seeded in the medium.
- collecting the reprogramming factor-introduced cells and seeding at least a part of the collected and mixed cells in a culture medium for passage means, for example, reprogramming factor-introduced cells, gene It refers to passaging without distinguishing between expression states.
- cells introduced with reprogramming factors may be seeded in the same culture vessel without being differentiated by gene expression state.
- recovering the cells introduced with the reprogramming factor, seeding at least a part of the recovered and mixed cells in a medium for passage means, for example, reprogramming the cells introduced with the reprogramming factor. It means to pass without distinguishing at the degree of.
- cells into which reprogramming factors have been introduced may be seeded in the same culture vessel without being differentiated by the degree of reprogramming.
- recovering the reprogramming factor-introduced cells and seeding at least a portion of the recovered and mixed cells in a medium for passaging means, for example, that the reprogramming factor-introduced cells are morphologically Passage without discrimination.
- cells into which reprogramming factors have been introduced may be seeded in the same culture vessel without being differentiated by morphology.
- recovering the reprogramming factor-introduced cells and seeding at least a portion of the recovered and mixed cells in a medium for passaging means, for example, reprogramming factor-introduced cells to a size It means to pass without distinction.
- cells into which reprogramming factors have been introduced may be seeded in the same culture vessel without size discrimination.
- recovering the reprogramming factor-introduced cells and seeding at least a portion of the recovered and mixed cells in a medium for passage means without cloning the reprogramming factor-introduced cells. It means to pass. For example, when passage without cloning, it is not necessary to pick up colonies formed by cells into which a reprogramming factor has been introduced. For example, when passaging without cloning, multiple colonies formed by cells into which a reprogramming factor has been introduced may not be separated from each other. For example, during passaging, cells forming different colonies may be mixed and seeded in the same culture vessel.
- a single colony formed by cells into which a reprogramming factor has been introduced may not be cloned.
- colonies may be mixed together and seeded in the same culture vessel during passaging.
- the adherently cultured cells may be collected, and at least a portion of the collected and mixed cells may be seeded in a medium for passage. good.
- cells may be detached from a culture vessel and at least a portion of the detached and mixed cells may be seeded into the same culture vessel.
- the cells may be detached from the incubator with a detachment solution, and the detached and mixed whole cells may be passaged.
- non-colony forming cells may be passaged.
- the whole cells in suspension culture may be subcultured.
- the cells When subculturing cells into which a reprogramming factor has been introduced, the cells may be seeded in a medium or incubator at a low concentration.
- the low concentration is, for example, 1 cell/cm 2 or more, 0.25 ⁇ 10 4 cells/cm 2 or less, 1.25 ⁇ 10 3 cells/cm 2 or less, or 0.25 ⁇ 10 3 cells/cm 2 or less. cm 2 or less, 0.25 ⁇ 10 2 cells/cm 2 or less, or 0.25 ⁇ 10 1 cells/cm 2 or less.
- low concentration means that 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less cells can contact each other.
- the concentration at which 11 or more cells do not come into contact with each other is a concentration at which 11 or more cells do not come into contact with each other.
- the state where the entire bottom surface of the cell container is covered with cells is 100% confluent, and low concentration means 5% or less confluent, 4% or less confluent, 3% or less confluent, 2% or less confluent, 1% or less confluent, 0 0.5% confluent, 0.1% confluent, 0.05% confluent, or 0.01% confluent.
- the low concentration is, for example, a concentration at which single cells do not contact each other in seeded cells.
- wells of a well plate may be seeded with single cells.
- a well plate may be a 12-well plate or a 96-well plate.
- the cells may be cultured at a predetermined temperature or higher at which the stability of the viral nucleic acid of the temperature-sensitive Sendai virus vector decreases after passage. After passage, the cells are cultured at a temperature of, for example, 36.5°C or higher and lower than 38.0°C. After passage, for example, the cells are cultured at a temperature of 36.5 ° C. or higher and less than 38.0 ° C. until intercellular adhesion starts, and after intercellular adhesion starts, a higher temperature until intercellular adhesion starts, For example, cells may be cultured at a temperature of 37.5°C or higher and 42.0°C or lower. After subculturing, the cells may be cultured at a temperature of 37.5° C. or higher and 42.0° C. or lower before cell-cell adhesion starts.
- Cells introduced with reprogramming factors may be cultured and passaged in a closed incubator.
- a closed incubator does not exchange, for example, gases, viruses, microorganisms and impurities with the outside.
- cells into which a reprogramming factor has been introduced may be expanded by two-dimensional culture, or expanded by three-dimensional culture.
- the whole adherent cultured cells may be cryopreserved as pluripotent stem cells.
- whole cells detached from the incubator with a detachment solution may be cryopreserved as pluripotent stem cells.
- the whole cells in suspension culture may be cryopreserved as pluripotent stem cells.
- Induced pluripotent stem cells can form flat-shouldered colonies similar to ES cells and express alkaline phosphatase. Induced pluripotent stem cells can express undifferentiated cell markers such as Nanog, OCT4, and SOX2. Induced pluripotent stem cells can express TERT. Induced pluripotent stem cells may exhibit temoutherase activity.
- a cytoflow meter which are cell surface markers indicating undifferentiated TRA-1-60, TRA-1-81, SSEA-1, and It may be done by analyzing whether at least one surface marker selected from SSEA5 is positive.
- TRA-1-60 is an antigen specific to iPS/ES cells. Since iPS cells can be generated only from the TRA-1-60 positive fraction, TRA-1-60 positive cells are considered to be iPS cell seeds.
- the method of introducing an inducer to oligodendrocytes into cells is not particularly limited.
- Inducers are introduced into cells, for example, by electroporation.
- inducers are introduced into cells by, for example, the lipofection method.
- the inducer is introduced into the cell using, for example, a viral vector.
- the inducer may be introduced into the cell integration-free.
- the cells into which the oligodendrocyte inducer is introduced may be adherent or suspension cultured.
- Somatic cells introduced with an inducer to oligodendrocytes are treated with basement membrane matrices such as Matrigel (Corning), CELLstart (registered trademark, ThermoFisher), Laminin511 (iMatrix-511, nippi), fibronectin, and vitrotin. , may be cultured feeder-free.
- basement membrane matrices such as Matrigel (Corning), CELLstart (registered trademark, ThermoFisher), Laminin511 (iMatrix-511, nippi), fibronectin, and vitrotin.
- stem cell medium such as Stemfit (Ajinomoto) and mTeSR (Stem Cell Technologies) can be used.
- a gel medium for example, is used when cells into which an inducer has been introduced are cultured in suspension or three-dimensionally.
- a gel medium is prepared, for example, by adding gellan gum to a stem cell medium.
- the gel medium contains gellan gum, hyaluronic acid, rhamsan gum, diutan gum, xanthan gum, carrageenan, fucoidan, pectin, pectic acid, pectinic acid, heparan sulfate, heparin, heparitin sulfate, keratosulfate, chondroitin sulfate, deltaman sulfate, rhamnan sulfate, and It may contain at least one polymer compound selected from the group consisting of salts thereof. Moreover, the gel medium may contain methylcellulose. Containing methylcellulose further suppresses aggregation between cells.
- the gel medium contains poly(glycerol monomethacrylate) (PGMA), poly(2-hydroxypropyl methacrylate) (PHPMA), Poly (N-isopropylacrylamide) (PNIPAM), amine terminated, carboxylic acid terminated, maleimide terminated, N-hydroxysuccinimide ( NHS) ester terminated, triethoxysilane terminated, Poly (N-isopropylacrylamide-co-acrylamide), Poly (N-isopropylacrylamide-co-acrylic acid), Poly (N-isopropylacrylamide-co-butylacrylate), Poly (N-isopropylacrylamide-co- methacrylic acid), Poly (N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate), and N-isopropylacrylamide.
- PGMA poly(glycerol monomethacrylate)
- PPMA poly(2-hydroxypropyl methacrylate)
- the gel medium may or may not contain growth factors such as basic fibroblast growth factor (bFGF).
- the gel medium may contain growth factors such as bFGF at low concentrations of 400 ⁇ g/L or less, 40 ⁇ g/L or less, or 10 ⁇ g/L or less.
- the gel medium may contain TGF- ⁇ , may not contain TGF- ⁇ , or may contain TGF- ⁇ at a low concentration of 600 ⁇ g/L or less, 300 ⁇ g/L or less, or 100 ⁇ g/L or less.
- the gel medium does not have to be stirred. Also, the gel medium may not contain feeder cells.
- the gel medium may contain at least one substance selected from the group consisting of cadherin, laminin, fibronectin, and vitronectin.
- the cells are produced within, for example, 30 days, 20 days, 10 days, or 7 days after the introduction of the inducer into the cells. It can be directed to oligodendrocytes.
- Immature oligodendrocytes such as oligodendrocyte progenitor cells and mature oligodendrocytes express at least one selected from O4 and PLP (Myelin Proteolipid Protein) 1 .
- Mature oligodendrocytes express MOG (Myelin Oligodendrocyte Glycoprotein) and PDGFR ⁇ (platelet-derived growth factor receptor ⁇ ).
- Example 1 A dish coated with laminin 511 was used as a dish for inducing pluripotent stem cells.
- human peripheral blood mononuclear cells were suspended in a blood medium, and the number of mononuclear cells was measured using a hemocytometer to adjust the number of mononuclear cells in the blood medium. After that, the mononuclear cells were two-dimensionally cultured on a dish for pluripotent stem cell induction at 37° C. for 1 to 7 days.
- SeV(PM) hKOS/TS12 ⁇ F and SeV(HNL) hC-Myc/TS15 ⁇ F were added to two-dimensionally cultured mononuclear cells at an MOI of 5, and a dish for inducing pluripotent stem cells was prepared. was placed in an incubator at 34° C. to culture the cells. Two days after infection, the blood medium was replaced with iPS cell medium. After that, the medium was changed once every two days using the iPS cell medium. On the way, the temperature was raised stepwise to 37°C and 38°C.
- stem cell-like cell clusters were generated. Almost all the cells became TRA1-60-positive cells on the 14th day after the infection, and exhibited an iPS cell-like morphology. 14 days after the infection, a cell detachment agent, Triple Select, was added to the dish, allowed to stand at room temperature for 1 minute, then the cell-containing solution was aspirated, and the cell-containing solution was incubated at 37°C for 5 to 10 minutes. . Thereafter, an iPS cell medium was added, and the iPS cell medium containing the cells was collected in a 15 mL tube.
- a cell detachment agent Triple Select
- Example 2 The number of cells was measured using a hemocytometer, the concentration of the cell-containing solution was adjusted, and the cells were seeded in a well plate so that the concentration was 0.25 ⁇ 10 4 cells/cm 2 or less. took over.
- Example 1 during the first passage, all cells were detached from the well plate and the detached and mixed cells were indiscriminately seeded in the next well plate.
- Example 2 colonies were picked and cloned during the first passage. In both Examples 1 and 2, the cells were seeded so that 11 or more cells did not come into contact with each other during passage.
- the well dish was placed in a 37° C. incubator to two-dimensionally culture the cells. After the cells began to divide, the culture temperature was raised to 38°C. After that, in both Examples 1 and 2, all the cells were collected every time the cells became 60% to 80% confluent, and at least a part of the collected and mixed cells was seeded in the medium and subcultured. . Cells were seeded in well plates at a concentration of 0.25 ⁇ 10 4 cells/cm 2 or less for the second and subsequent passages. Also in this case, 11 or more cells did not contact each other.
- the number of colonies formed 5 days after the Sendai virus disappeared in the cells was counted.
- clonal efficiency was calculated by dividing the number of colonies by the number of cells plated. The results of three tests are shown in FIG. When all cells are harvested at the first passage using mTeSR Plus as the medium, and some of the harvested and mixed cells are plated in the medium and passaged, the clonal efficiency ranges from about 5%. It was about 8%, and the variation was small. When using mTeSR Plus as the medium and cloning by colony picking at the first passage, the clonal efficiency is sometimes less than 1% and sometimes about 6%. There was variability.
- Clonal efficiency is about 10% to about 10% when all cells are harvested at the first passage using StemFit in the medium and some of the harvested mixed cells are plated in the medium and passaged. 15%, and the variation was small.
- the clonal efficiency is sometimes less than 1% and sometimes about 16%, and the clonal efficiency varies. was there.
- Example 3 A well dish coated with a solubilized basement membrane preparation (Matrigel, Corning) was prepared, and ROCK (Rho-associated coiled-coil forming kinase) inhibitor (Selleck) was added to each well at a concentration of 10 nmol/mL.
- ROCK Rho-associated coiled-coil forming kinase inhibitor
- Human iPS cells were dispersed with a tissue/culture cell detachment/separation/dispersion solution (Accutase, Innovative Cell Technologies) and seeded in a well dish. After that, the iPS cells were cultured for 24 hours in a feeder-free medium under gaseous conditions of 5% carbon dioxide concentration and 20% oxygen concentration.
- a single-cell suspension was prepared by detaching the iPS cells from the wells using a detachment agent.
- OLIG2, SOX10, ASCL1, and NKX2.2 as inducers were introduced into iPS cells by electroporation using a Human Stem Cell Nucleofector Kit (registered trademark, LONZA) and an episomal plasmid. After that, the inducer-introduced cells were seeded in a well dish and cultured in mTeSR.
- Oligodendrocyte medium contains DMEM/F12, N2 (1X), B27 (1X), penicillin-streptomycin (1X), NEAA (1X), insulin (25 ⁇ g/mL, Sigma), PDGF-AA (10 ng/ml, PeproTech), IGF (10 ng/mL, PeproTech), NT3 (1 ng/mL, PeproTech), biotin (100 ng/mL, Sigma), and cAMP (1 ⁇ mol/L, Sigma).
- the wells were also supplemented with oligodendrocyte medium.
- the inducer-introduced cells were seeded on human fibroblasts or human glial cells, and the inducer-introduced cells were cultured until 21 days.
- Cells on day 7 after introduction of the inducer were stained with an anti-O4 antibody.
- the cells 21 days after introduction of the inducer were stained with anti-O4 antibody, anti-PLP1 antibody, and anti-MOG antibody.
- the cells 7 days after the introduction of the inducer expressed O4, a marker for oligodendrocytes and their progenitor cells.
- O4, PLP1, and MOG were expressed in the cells 21 days after introduction of the inducer. Whether the iPS cells to be introduced with the inducer are the iPS cells prepared in Example 1 or the iPS cells prepared in Example 2, the expression of markers for oligodendrocytes and their progenitor cells is confirmed.
- Example 4 Inducing factors were introduced into iPS cells in the same manner as in Example 3, except that OLIG2, SOX10, ASCL1 and NKX6.1 were used as inducers. As shown in FIG. 7, the inducer-introduced cells expressed O4.
- Example 5 Inducing factors were introduced into iPS cells in the same manner as in Example 3, except that OLIG2, SOX10, and ASCL1 were used as inducers. As shown in FIG. 8(a), the inducer-introduced cells expressed O4.
- Example 6 Inducing factors were introduced into iPS cells in the same manner as in Example 3, except that OLIG2 and SOX10 were used as inducers. As shown in FIG. 8(b), the inducer-introduced cells expressed O4.
- Example 7 Inducing factors were introduced into iPS cells in the same manner as in Example 3, except that OLIG2 and ASCL1 were used as inducers. As shown in FIG. 8(c), the inducer-introduced cells expressed O4.
- Example 8 An inducer was introduced into iPS cells in the same manner as in Example 3, except that OLIG2 was used as the inducer. As shown in FIG. 8(d), the inducer-introduced cells expressed O4.
- Example 9 Inducing factors were introduced into iPS cells in the same manner as in Example 3, except that OLIG2 and NKX2.2 were used as inducers. As shown in FIG. 8(e), the inducer-introduced cells expressed O4, a marker for oligodendrocytes and their progenitor cells.
- Example 10 A well dish coated with a solubilized basement membrane preparation (Matrigel, Corning) was prepared and media was added to each well. In addition, Ficoll (GE)-separated human adult peripheral blood mononuclear cells were seeded in well dishes. Mononuclear cells were then cultured in blood medium (StemSpan®, SFEM II, STEMCELL TECHNOLOGIES) at 37° C. for 1 to 7 days. Medium contained 20 ng/mL FLT3, 10 ng/mL TPO, 50 ng/mL IL6, 10 ng/mL GCSF, 50 ng/mL SCF, 20 ng/mL IL3, 10 ng/mL GM-CSF. . It was cultured on a dish under gaseous conditions of 5% carbon dioxide concentration and 20% oxygen concentration.
- the mononuclear cells were collected from the wells and a single cell suspension was prepared. Next, OLIG2, SOX10, ASCL1 and NKX2.2 as inducers were introduced into mononuclear cells by electroporation using a Nucleofector kit for CD34+ cells (registered trademark, LONZA) and an episomal plasmid. After that, the inducer-introduced cells were seeded in a well dish and cultured in blood medium.
- OLIG2, SOX10, ASCL1 and NKX2.2 as inducers were introduced into mononuclear cells by electroporation using a Nucleofector kit for CD34+ cells (registered trademark, LONZA) and an episomal plasmid. After that, the inducer-introduced cells were seeded in a well dish and cultured in blood medium.
- oligodendrocyte medium was added to the wells.
- the wells were also supplemented with oligodendrocyte medium.
- all medium in the wells was replaced with fresh oligodendrocyte medium.
- the inducer-introduced cells were seeded on human fibroblasts, and the inducer-introduced cells were cultured until 28 days.
- Cells 28 days after introduction of the inducer were stained with anti-O4 antibody, anti-PLP1 antibody and anti-MOG antibody, respectively. As shown in FIG. 9, cells 28 days after introduction of the inducer expressed O4, PLP1 and MOG.
- Example 11 A well dish coated with a solubilized basement membrane preparation (Matrigel, Corning) was prepared and medium (DMEM containing 10% FBS) was added to each well. In addition, human neonatal fibroblasts were seeded in well dishes. The fibroblasts were then cultured on the dish at 37° C. for 1 to 7 days under gaseous conditions of 5% carbon dioxide concentration and 20% oxygen concentration.
- Fibroblasts were detached from the wells using a detachment agent to prepare a single-cell suspension.
- OLIG2, SOX10, ASCL1, and NKX2.2 as inducers were introduced into fibroblasts by electroporation using a Human Dermal Fibroblast Nucleofector Kit (registered trademark, LONZA) and an episomal plasmid.
- LONZA Human Dermal Fibroblast Nucleofector Kit
- the inducer-introduced cells were seeded in a well dish and cultured in a 10% FBS DMEM medium.
- oligodendrocyte medium was added to the wells.
- the wells were also supplemented with oligodendrocyte medium.
- all medium in the wells was replaced with fresh oligodendrocyte medium.
- the inducer-introduced cells were seeded on human fibroblasts, and the inducer-introduced cells were cultured until 28 days.
- Cells 28 days after introduction of the inducer were stained with anti-O4 antibody, anti-PLP1 antibody and anti-MOG antibody, respectively. As shown in FIG. 10, cells 28 days after introduction of the inducer expressed O4, PLP1 and MOG.
- Example 12 A well dish coated with a solubilized basement membrane preparation (Matrigel, Corning) was prepared and media was added to each well. In addition, human adult peripheral blood-derived T cells were seeded in well dishes. After that, the T cells were expanded on a dish at 37° C. for 1 to 7 days under gaseous conditions of 5% carbon dioxide concentration and 20% oxygen concentration. Note that the expansion culture does not necessarily have to be performed.
- a serum-free medium (X-VIVO10, Lonza) supplemented with 30 U/mL interleukin-2 and beads for human T cell proliferation stimulation (Dynabeas CD3/CD28, BD) was used.
- T cells were collected from the wells and a single cell suspension was prepared.
- OLIG2, SOX10, ASCL1 and NKX2.2 as inducers were introduced into mononuclear cells by electroporation using a Tcell electroporation kit (registered trademark, LONZA) and an episomal plasmid. After that, the inducer-introduced cells were seeded in a well dish, and serum-free medium (X-VIVO10 , Lonza).
- oligodendrocyte medium was added to the wells.
- the wells were also supplemented with oligodendrocyte medium.
- all medium in the wells was replaced with fresh oligodendrocyte medium.
- the inducer-introduced cells were seeded on human fibroblasts, and the inducer-introduced cells were cultured until 28 days.
- Cells 28 days after introduction of the inducer were stained with anti-O4 antibody, anti-PLP1 antibody and anti-MOG antibody, respectively. As shown in FIG. 11, cells 28 days after introduction of the inducer expressed O4, PLP1 and MOG.
- Example 13 Oligodendrocytes were induced from human iPS cells in the same manner as in Example 3, except that p53DD was added as an inducer. The results are shown in FIG. Addition of p53DD increased the percentage of cells showing O4 positivity.
- Example 14 Oligodendrocytes were induced from human iPS cells in the same manner as in Example 3, except that RB gene shRNA was added to the inducer. The results are shown in FIG. Addition of Rb Sh increased the percentage of cells showing O4 positivity.
- Example 15 Oligodendrocytes were induced from human iPS cells in the same manner as in Example 3, except that c-MYC was added as an inducer. The results are shown in FIG. Addition of c-MYC increased the percentage of cells showing O4 positivity.
- Example 16 Oligodendrocytes were induced from human adult peripheral blood-derived mononuclear cells in the same manner as in Example 10, except that p53DD was added as an inducer. The results are shown in FIG. Addition of p53DD increased the percentage of cells showing O4 positivity.
- Example 17 Oligodendrocytes were induced from human adult peripheral blood-derived mononuclear cells in the same manner as in Example 10, except that RB Sh was added as an inducer. The results are shown in FIG. Addition of Rb Sh increased the percentage of cells showing O4 positivity.
- Example 18 Oligodendrocytes were induced from human adult peripheral blood-derived mononuclear cells in the same manner as in Example 10, except that c-MYC was added as an inducer. The results are shown in FIG. Addition of c-MYC increased the percentage of cells showing O4 positivity.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
ラミニン511をコートしたディッシュを、多能性幹細胞誘導用のディッシュとした。また、ヒト末梢血単核球細胞を血液培地に懸濁し、血球計算版を用いて単核球細胞の数を測定して、血液培地における単核球細胞数を調整した。その後、単核球細胞を、37℃で1日間から7日間、多能性幹細胞誘導用のディッシュ上で二次元培養した。
(実施例3)
可溶化基底膜調製品(Matrigel、Corning)でコートされたウェルディッシュを用意し、各ウェルに10nmol/mLの濃度でROCK(Rho-associated coiled-coil forming kinase/Rho結合キナーゼ)阻害剤(Selleck)を含むフィーダーフリー培地(mTeSR(登録商標)1、Stemcell Technologies)を入れた。
誘導因子としてOLIG2、SOX10、ASCL1、NKX6.1を用いた以外は、実施例3と同様に、iPS細胞に誘導因子を導入した。図7に示すように、誘導因子を導入された細胞は、O4を発現していた。
誘導因子としてOLIG2、SOX10、ASCL1を用いた以外は、実施例3と同様に、iPS細胞に誘導因子を導入した。図8(a)に示すように、誘導因子を導入された細胞は、O4を発現していた。
誘導因子としてOLIG2、SOX10を用いた以外は、実施例3と同様に、iPS細胞に誘導因子を導入した。図8(b)に示すように、誘導因子を導入された細胞は、O4を発現していた。
誘導因子としてOLIG2、ASCL1を用いた以外は、実施例3と同様に、iPS細胞に誘導因子を導入した。図8(c)に示すように、誘導因子を導入された細胞は、O4を発現していた。
誘導因子としてOLIG2を用いた以外は、実施例3と同様に、iPS細胞に誘導因子を導入した。図8(d)に示すように、誘導因子を導入された細胞は、O4を発現していた。
誘導因子としてOLIG2、NKX2.2を用いた以外は、実施例3と同様に、iPS細胞に誘導因子を導入した。図8(e)に示すように、誘導因子を導入された細胞は、オリゴデンドロサイト及びその前駆細胞のマーカーであるO4を発現していた。
可溶化基底膜調製品(Matrigel、Corning)でコートされたウェルディッシュを用意し、各ウェルに培地を入れた。さらに、Ficoll(GE)で分離したヒト成人末梢血由来単核球を、ウェルディッシュに播種した。その後、単核球を、37℃で1日間から7日間、血液培地(StemSpan、登録商標、SFEM II、STEMCELL TECHNOLOGIES)で培養した。培地は、20ng/mLのFLT3、10ng/mLのTPO、50ng/mLのIL6、10ng/mLのGCSF、50ng/mLのSCF、20ng/mLのIL3、10ng/mLのGM-CSFを含んでいた。5%二酸化炭素濃度及び20%酸素濃度の気体条件下で、ディッシュ上で培養した。
可溶化基底膜調製品(Matrigel、Corning)でコートされたウェルディッシュを用意し、各ウェルに培地(10%FBS含有DMEM)を入れた。さらに、ヒト新生児線維芽細胞を、ウェルディッシュに播種した。その後、線維芽細胞を、37℃で1日間から7日間、5%二酸化炭素濃度及び20%酸素濃度の気体条件下で、ディッシュ上で培養した。
可溶化基底膜調製品(Matrigel、Corning)でコートされたウェルディッシュを用意し、各ウェルに培地を入れた。さらに、ヒト成人末梢血由来T細胞を、ウェルディッシュに播種した。その後、T細胞を、37℃で1日間から7日間、5%二酸化炭素濃度及び20%酸素濃度の気体条件下で、ディッシュ上で拡大培養した。なお、拡大培養は、必ずしもしなくともよい。30U/mLのインターロイキン2及びヒトT細胞増殖刺激用ビーズ(Dynabeas CD3/CD28、BD)を添加した培地無血清培地(X-VIVO10、Lonza)を用いた。
誘導因子にp53DDを加えた以外は、実施例3と同様に、ヒトiPS細胞からオリゴデンドロサイトを誘導した。結果を図12に示す。p53DDを加えると、O4陽性を示す細胞の割合が上昇した。
誘導因子にRB遺伝子のshRNAを加えた以外は、実施例3と同様に、ヒトiPS細胞からオリゴデンドロサイトを誘導した。結果を図12に示す。Rb Shを加えると、O4陽性を示す細胞の割合が上昇した。
誘導因子にc-MYCを加えた以外は、実施例3と同様に、ヒトiPS細胞からオリゴデンドロサイトを誘導した。結果を図12に示す。c-MYCを加えると、O4陽性を示す細胞の割合が上昇した。
誘導因子にp53DDを加えた以外は、実施例10と同様に、ヒト成人末梢血由来単核球からオリゴデンドロサイトを誘導した。結果を図12に示す。p53DDを加えると、O4陽性を示す細胞の割合が上昇した。
誘導因子にRB Shを加えた以外は、実施例10と同様に、ヒト成人末梢血由来単核球からオリゴデンドロサイトを誘導した。結果を図12に示す。Rb Shを加えると、O4陽性を示す細胞の割合が上昇した。
誘導因子にc-MYCを加えた以外は、実施例10と同様に、ヒト成人末梢血由来単核球からオリゴデンドロサイトを誘導した。結果を図12に示す。c-MYCを加えると、O4陽性を示す細胞の割合が上昇した。
Claims (29)
- iPS細胞又はES細胞にOLIG及びSOXの組み合わせ、又はOLIG及びNKXの組み合わせを含む誘導因子を導入することを含む、オリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子がOLIG、NKX、及びSOXを含む、請求項1に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子がASCLをさらに含む、請求項1又は2に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子が、細胞増殖を促進する因子をさらに含む、請求項1から3のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- iPS細胞又はES細胞にOLIG及び細胞増殖を促進する因子を含む誘導因子を導入することを含む、オリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子がSOX、ASCL、及びNKXからなる群から選択される少なくともいずれかを含む、請求項5に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- リプログラミング因子を導入された細胞をクローニングせずにiPS細胞を作製することと、
前記iPS細胞にOLIGを含む誘導因子を導入することと、
を含む、オリゴデンドロサイト及びその前駆細胞の作製方法。 - リプログラミング因子を導入された細胞をクローニングせずに播種し、iPS細胞を作製することと、
前記iPS細胞にOLIGを含む誘導因子を導入することと、
を含む、オリゴデンドロサイト及びその前駆細胞の作製方法。 - リプログラミング因子を導入された細胞を培養器から剥離し、剥離した細胞の少なくとも一部を混合して播種し、iPS細胞を作製することと、
前記iPS細胞にOLIGを含む誘導因子を導入することと、
を含む、オリゴデンドロサイト及びその前駆細胞の作製方法。 - リプログラミング因子を導入された細胞を培養器から回収し、回収した細胞の少なくとも一部を混合して播種し、iPS細胞を作製することと、
前記iPS細胞にOLIGを含む誘導因子を導入することと、
を含む、オリゴデンドロサイト及びその前駆細胞の作製方法。 - リプログラミング因子を導入された細胞が形成する複数のコロニーのそれぞれをピックアップせずにiPS細胞を作製することと、
前記iPS細胞にOLIGを含む誘導因子を導入することと、
を含む、オリゴデンドロサイト及びその前駆細胞の作製方法。 - リプログラミング因子を導入された細胞であって、異なるシングルセル由来の細胞同士混合して播種してiPS細胞を作製することと、
前記iPS細胞にOLIGを含む誘導因子を導入することと、
を含む、オリゴデンドロサイト及びその前駆細胞の作製方法。 - 前記播種することにおいて、前記リプログラミング因子を導入された細胞同士を混合する、請求項9、10、及び12のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記播種することにおいて、前記リプログラミング因子を導入された細胞のクローン同士を混合する、請求項9、10、12、及び13のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記リプログラミング因子を導入された細胞が形成する複数のコロニーを互いに分離することを含まない、請求項7から14のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記播種することにおいて、前記リプログラミング因子を導入された細胞が形成する複数のコロニーを互いに混合する、請求項9、10、12、13、及び14のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記リプログラミング因子を導入された細胞が形成する単一のコロニーをクローニングすることを含まない、請求項7から16のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記リプログラミング因子を導入された細胞であって、培養器に付着している細胞を回収し、回収した細胞の少なくとも一部を培地に播種する、請求項7から17のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記リプログラミング因子を導入された細胞を遺伝子発現状態で区別することなく播種する、請求項7から18のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記リプログラミング因子を導入された細胞をリプログラミングの程度で区別することなく播種する、請求項7から19のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子がSOX、ASCL、及びNKXからなる群から選択される少なくともいずれかを含む、請求項7から20のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 体細胞にOLIG、SOX、ASCL、NKXを含む誘導因子を導入することを含む、オリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子が、細胞増殖を促進する因子をさらに含む、請求項22に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 体細胞にOLIG及び細胞増殖を促進する因子を含む誘導因子を導入することを含む、オリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記誘導因子がSOX、ASCL、及びNKXからなる群から選択される少なくともいずれかを含む、請求項24に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記体細胞がiPS細胞又はES細胞でない、請求項22から25のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記体細胞が血液細胞である、請求項22から26のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記体細胞が単核球である、請求項22から26のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
- 前記体細胞が線維芽細胞である、請求項22から26のいずれか1項に記載のオリゴデンドロサイト及びその前駆細胞の作製方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022578285A JP7536245B2 (ja) | 2021-01-26 | 2022-01-19 | オリゴデンドロサイトの作製方法 |
US18/258,778 US20240093146A1 (en) | 2021-01-26 | 2022-01-19 | Method for producing oligodendrocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163141626P | 2021-01-26 | 2021-01-26 | |
US63/141,626 | 2021-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022163466A1 true WO2022163466A1 (ja) | 2022-08-04 |
Family
ID=82653355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/001814 WO2022163466A1 (ja) | 2021-01-26 | 2022-01-19 | オリゴデンドロサイトの作製方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240093146A1 (ja) |
JP (1) | JP7536245B2 (ja) |
WO (1) | WO2022163466A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069666A1 (ja) * | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
US20190322981A1 (en) * | 2016-07-05 | 2019-10-24 | Westfaelische Wilhelms-Universitaet Muenster | Means and methods for the generation of oligodendrocytes |
JP2020501533A (ja) * | 2016-11-24 | 2020-01-23 | ケンブリッジ エンタープライズ リミテド | 制御可能な転写 |
-
2022
- 2022-01-19 WO PCT/JP2022/001814 patent/WO2022163466A1/ja active Application Filing
- 2022-01-19 US US18/258,778 patent/US20240093146A1/en active Pending
- 2022-01-19 JP JP2022578285A patent/JP7536245B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007069666A1 (ja) * | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
US20190322981A1 (en) * | 2016-07-05 | 2019-10-24 | Westfaelische Wilhelms-Universitaet Muenster | Means and methods for the generation of oligodendrocytes |
JP2020501533A (ja) * | 2016-11-24 | 2020-01-23 | ケンブリッジ エンタープライズ リミテド | 制御可能な転写 |
Non-Patent Citations (3)
Title |
---|
CHANOUMIDOU KONSTANTINA, HERNÁNDEZ-RODRÍGUEZ BENJAMÍN, WINDENER FARINA, THOMAS CHRISTIAN, STEHLING MARTIN, MOZAFARI SABAH, ALBRECH: "One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2", STEM CELL REPORTS, CELL PRESS, UNITED STATES, vol. 16, no. 4, 1 April 2021 (2021-04-01), United States , pages 771 - 783, XP055955418, ISSN: 2213-6711, DOI: 10.1016/j.stemcr.2021.03.001 * |
MARC EHRLICH, SABAH MOZAFARI, MICHAEL GLATZA, LAURA STAROST, SERGIY VELYCHKO, ANNA-LENA HALLMANN, QIAO-LING CUI, AXEL SCHAMBACH, K: "Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 114, no. 11, 14 March 2017 (2017-03-14), pages E2243 - E2252, XP055405501, ISSN: 0027-8424, DOI: 10.1073/pnas.1614412114 * |
MATTHIAS PAWLOWSKI, DANIEL ORTMANN, ALESSANDRO BERTERO, JOANA M. TAVARES, ROGER A. PEDERSEN, LUDOVIC VALLIER, MARK R.N. KOTTER: "Inducible and Deterministic Forward Programming of Human Pluripotent Stem Cells into Neurons, Skeletal Myocytes, and Oligodendrocytes", STEM CELL REPORTS, CELL PRESS, UNITED STATES, vol. 8, no. 4, 1 April 2017 (2017-04-01), United States , pages 803 - 812, XP055441144, ISSN: 2213-6711, DOI: 10.1016/j.stemcr.2017.02.016 * |
Also Published As
Publication number | Publication date |
---|---|
JP7536245B2 (ja) | 2024-08-20 |
JPWO2022163466A1 (ja) | 2022-08-04 |
US20240093146A1 (en) | 2024-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240228977A1 (en) | Generation of induced pluripotent stem cells from small volumes of peripheral blood | |
US11970714B2 (en) | Method for reprogramming blood to induced pluripotent stem cells | |
JP5963309B2 (ja) | 末梢血単球由来多能性幹細胞作製方法 | |
US20210371828A1 (en) | Induced pluripotent cell comprising a controllable transgene for conditional immortalization | |
JP2021176315A (ja) | 神経系細胞の作製方法 | |
WO2021209756A1 (en) | Induced pluripotent cell comprising a controllable transgene for conditional immortalisation | |
WO2022163466A1 (ja) | オリゴデンドロサイトの作製方法 | |
WO2013095910A1 (en) | Induced pluripotent stem cells prepared from human kidney-derived cells | |
WO2021149822A1 (ja) | 人工多能性幹細胞の作製方法 | |
WO2021149824A1 (ja) | 人工多能性幹細胞の作製方法 | |
US20220213446A1 (en) | Method for culturing cells into which reprogramming factor is introduced | |
US20230061798A1 (en) | Method for culturing factor-introduced cells | |
WO2023053994A1 (ja) | 幹細胞の製造方法 | |
CN117736974A (zh) | Dapt在维持扩展多潜能干细胞多能性及提高其增殖能力中的应用 | |
Marttila | Establishment and characterisation of new human induced pluripotent stem cell lines and cardiomyocyte differentiation: a comparative view |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22745687 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022578285 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18258778 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22745687 Country of ref document: EP Kind code of ref document: A1 |